Nalaganje...
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in thi...
Shranjeno v:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2978257/ https://ncbi.nlm.nih.gov/pubmed/20827286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2010.190 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|